CVRx reported first-quarter 2026 revenue of $14.8 million, up 20% year over year, and said results exceeded the high end of guidance. Growth in its U.S. Barostim heart failure business was the main driver of the upside. The quarter points to improving operating momentum and should be modestly supportive for the stock.
CVRx reported first-quarter 2026 revenue of $14.8 million, up 20% year over year, and said results exceeded the high end of guidance. Growth in its U.S. Barostim heart failure business was the main driver of the upside. The quarter points to improving operating momentum and should be modestly supportive for the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.56
Ticker Sentiment
